Science

Jan 15, 2025, 14:04

Akhil Santhosh: Primary efficacy and safety results from the AMALEE trial

Akhil Santhosh, Medical Oncologist at AIIMS Delhi, shared an article by Fatima Cardoso on X:

“Primary efficacy and safety results from the AMALEE trial evaluating 600 vs 400 mg starting doses of first-line ribociclib in patients with advanced BC.

400mg ribo has a better side effect profile but failed to meet non inferiority vs 600mg.”

Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer.

Authors: Fatima Cardoso, et al.

Akhil Santhosh: Primary efficacy and safety results from the AMALEE trial

More posts featuring Akhil Santhosh.

Abstract PD17-12 AIIMS DELHI Akhil Santhosh AMALEE trial Breast Cancer cancer Fatima Cardoso fight against cancer Global fight against cancer OncoDaily Oncology Ribociclib

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage